<DOC>
	<DOCNO>NCT02914561</DOCNO>
	<brief_summary>The primary objective study evaluate safety efficacy filgotinib induction maintenance treatment moderately severely active Crohn 's disease ( CD ) participants biologic-naive biologic-experienced . Participants complete study , meet protocol response remission criterion Week 10 option enter separate long-term extension ( LTE ) study ( Gilead Study GS-US-419-3896 ) .</brief_summary>
	<brief_title>Filgotinib Induction Maintenance Remission Adults With Moderately Severely Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Key Males nonpregnant , nonlactating female , age 18 75 year , inclusive base date screen visit Documented diagnosis CD minimum disease duration 6 month involvement ileum and/or colon minimum , determine histopathology endoscopic assessment Moderately severely active CD Previously demonstrate inadequate clinical response , loss response , intolerance least 1 follow agent : corticosteroid , immunomodulators , tumor necrosis factor alpha ( TNFa ) antagonists , vedolizumab Key Current complication CD symptomatic stricture , severe rectal/anal stenosis , fistula , short bowel syndrome , etc . Presence ulcerative colitis , indeterminate colitis , ischemic colitis , fulminant colitis , toxic megacolon Active tuberculosis ( TB ) history latent TB treat Use prohibit concomitant medication describe study protocol NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>